Drug Interactions between Idhifa and Targretin
This report displays the potential drug interactions for the following 2 drugs:
- Idhifa (enasidenib)
- Targretin (bexarotene)
Interactions between your drugs
No interactions were found between Idhifa and Targretin. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Idhifa
A total of 79 drugs are known to interact with Idhifa.
- Idhifa is in the drug class miscellaneous antineoplastics.
- Idhifa is used to treat Acute Myeloid Leukemia.
Targretin
A total of 619 drugs are known to interact with Targretin.
- Targretin is in the drug class miscellaneous antineoplastics.
- Targretin is used to treat Cutaneous T-cell Lymphoma.
Drug and food interactions
bexarotene food
Applies to: Targretin (bexarotene)
ADJUST DOSING INTERVAL: Food may enhance the oral bioavailability of bexarotene. In one clinical study, bexarotene peak plasma concentration (Cmax) and systemic exposure (AUC) resulting from a 75 to 300 mg dose were 35% and 48% higher, respectively, when administered after a fat-containing meal relative to a glucose solution. In all clinical trials, patients were instructed to take bexarotene with or immediately following a meal.
Coadministration with inhibitors of CYP450 3A4 such as grapefruit juice may theoretically increase the plasma concentrations of bexarotene. In vitro studies suggest that bexarotene is metabolized by CYP450 3A4. However, concomitant administration with multiple doses of ketoconazole, a potent CYP450 3A4 inhibitor, did not alter bexarotene plasma concentrations, which would imply that bexarotene elimination is not substantially dependent on CYP450 3A4 metabolism in vivo.
MANAGEMENT: Because safety and efficacy data are based upon administration with food, bexarotene should be administered once daily with a meal. Patients may want to avoid consuming large amounts of grapefruit or grapefruit juice.
References
- (2001) "Product Information. Targretin (bexarotene)." Ligand Pharmaceuticals
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.